This is a working overview of immunomodulatory peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
The A form occurs under non-physiological conditions in partly dehydrated samples of DNA, while in the cell it may be produced in hybrid pairings of DNA and RNA strands, and in enzyme-DNA complexes. Segments of DNA where the bases have been chemically modified by methylation may undergo a larger change in conformation and adopt the Z form. Here, the strands turn about the helical axis in a left-handed spiral, the opposite of the more common B form. These unusual structures can be recognized by specific Z-DNA binding proteins and may be involved in the regulation of transcription.
=== Diagnostic tests === Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence of this substance. Proteins can be detected using the Western blot and immuno dot blot tests. In immunohistochemistry, monoclonal antibodies can be used to detect antigens in fixed tissue sections, and similarly, immunofluorescence can be used to detect a substance in either frozen tissue section or live cells.
== Cultural response == Though intended as a parody, the single popularized the valley girl stereotype nationwide. Following the single's release, there was a significant increase in "valleyspeak" slang usage, whether ironically spoken or not. In particular, the film Valley Girl (1983) capitalized on this cultural curiosity. Zappa expressed concern that, despite his rich body of music, he was seen as a "novelty" artist because of songs like "Valley Girl" and "Don't Eat the Yellow Snow". At the time of the single's release, Moon said, "I am not a valley girl, but I guess that is my claim to fame." Mimi Pond created a comic book about the song, The Valley Girl's Guide to Life, which launched her career. A parody entitled "Valley Dudes" was recorded in 1982 by The Straight A's. On September 16, 2022 (3 months after the single's 40th anniversary), Universal Music Group (who acquired the Zappa catalogue in June of the same year) released an animated music video for the song.
Sources: en.wikipedia.org
KH-001 is an atypical serotonin reuptake inhibitor (SRI) and phosphodiesterase (PDE) inhibitor which is under development for the treatment of premature ejaculation. It is taken on-demand orally. The drug is a purified alkaloid derived from the South African plant Sceletium tortuosum (kanna). It is said to be selective and to have high potency as a serotonin reuptake inhibitor and phosphodiesterase inhibitor. In addition, KH-001 has atypical properties as a serotonin reuptake inhibitor, including a rapid onset of therapeutic effectiveness rather than requiring chronic administration. KH-001 has been found to increase latency to ejaculation in male rats treated acutely with para-chloroamphetamine (PCA) to induce ejaculation. The pharmacokinetics of KH-001 in humans have been studied. It showed a rapid onset and a short duration. The drug is described as a potential first-in-class medication. KH-001 is under development by Kadence Bio (formerly Kanna Health). As of November 2024, it is in phase 1 clinical trials. Phase 2 trials were planned to begin in 2025. The chemical structure of KH-001 does not yet appear to have been disclosed. However, Kanna Health patented synthetic analogues of mesembrine with activity as serotonin reuptake inhibitors in 2023, with KH-001 being indicated as one of the compounds in the patent.
=== Aortic stenosis === Treatment of aortic stenosis is not necessary in asymptomatic patients, unless the stenosis is classified as severe based on valve hemodynamics. Both asymptomatic severe and symptomatic aortic stenosis are treated with aortic valve replacement (AVR) surgery. AVR surgery can be performed using mechanical or tissue valves depending on age and other relevant factors. Trans-catheter Aortic Valve Implantation (TAVI) is an alternative to AVR and is recommended in high risk patients who may not be suitable for surgical AVR. Any angina is treated with short-acting nitrovasodilators, beta-blockers and/or calcium blockers, although nitrates can drastically decrease blood pressure in patients with severe aortic stenosis and are therefore contraindicated. Any hypertension is treated aggressively, but caution must be taken in administering beta-blockers. Any heart failure is treated with digoxin, diuretics, nitrovasodilators and, if not contraindicated, cautious inpatient administration of ACE inhibitors. Moderate stenosis is monitored with echocardiography every 1–2 years, possibly with supplementary cardiac stress test. Severe stenosis should be monitored with echocardiography every 3–6 months.
== Side effects == Possible side effects of cyanocobalamin injection include allergic reactions such as hives, difficult breathing; redness of the face; swelling of the arms, hands, feet, ankles or lower legs; extreme thirst; and diarrhea. Less-serious side effects may include headache, dizziness, leg pain, itching, or rash. Treatment of megaloblastic anemia with concurrent vitamin B12 deficiency using B12 vitamers (including cyanocobalamin), creates the possibility of hypokalemia due to increased erythropoiesis (red blood cell production) and consequent cellular uptake of potassium upon anemia resolution. When treated with cyanocobalamin, patients with Leber's disease may develop serious optic atrophy, possibly leading to blindness, based on few case reports.
==== Blockage of the ejaculatory duct ==== This is a condition that is caused by obstruction of either one or both ejaculatory ducts leading to hypospermia. The etiology of ejaculatory duct obstruction can be congenital or acquired. The presence of a prostatic cysts, ejaculatory duct stones, or post surgical inflammation of the duct can block the normal flow of semen through the reproductive tract.
Sources: en.wikipedia.org
The fruit bodies of Boletus edulis can grow singly or in small clusters of two or three specimens. The mushroom's habitat consists of areas dominated by pine (Pinus spp.), spruce (Picea spp.), hemlock (Tsuga spp.) and fir (Abies spp.) trees, although other hosts include chestnut, chinquapin, beech, Keteleeria spp., Lithocarpus spp., and oak. In California, porcini have been collected in a variety of forests, such as coastal forests, dry interior oak forests and savannas and interior high-elevation montane mixed forests, to an altitude of 3,500 m (11,500 ft). In northwestern Spain, they are common in scrublands dominated by the rock rose species Cistus ladanifer and Halimium lasianthum. In the Midi region of south-west France, they are especially favoured and locally called cèpe de Bordeaux after the town from which they are traded to the north and abroad. Boletus edulis has a cosmopolitan distribution, concentrated in cool-temperate to subtropical regions. It is common in Europe—from northern Scandinavia, south to the extremities of Greece and Italy—and North America, where its southern range extends as far south as Mexico. It is well known from the Borgotaro area of Parma, Italy, and has PGI status there. The European distribution extends north to Scandinavia and south to southern Italy and Morocco. In North America, it can be found from May to October inland and August to January on the West Coast. In China, the mushroom can be found from the northeastern Heilongjiang to the Yunnan–Guizhou Plateau and Tibet.
FAD can be reduced to FADH2 through the addition of 2 H+ and 2 e−. FADH2 can also be oxidized by the loss of 1 H+ and 1 e− to form FADH. The FAD form can be recreated through the further loss of 1 H+ and 1 e−. FAD formation can also occur through the reduction and dehydration of flavin-N(5)-oxide. Based on the oxidation state, flavins take specific colors when in aqueous solution. Flavin-N(5)-oxide (super oxidized) is yellow-orange, FAD (fully oxidized) is yellow, FADH (half reduced) is either blue or red based on the pH, and the fully reduced form is colorless. Changing the form can have a large impact on other chemical properties. For example, FAD, the fully oxidized form is subject to nucleophilic attack, the fully reduced form, FADH2 has high polarizability, while the half reduced form is unstable in aqueous solution. FAD is an aromatic ring system, whereas FADH2 is not. This means that FADH2 is significantly higher in energy, without the stabilization through resonance that the aromatic structure provides. FADH2 is an energy-carrying molecule, because, once oxidized it regains aromaticity and releases the energy represented by this stabilization. The spectroscopic properties of FAD and its variants allows for reaction monitoring by use of UV-VIS absorption and fluorescence spectroscopies. Each form of FAD has distinct absorbance spectra, making for easy observation of changes in oxidation state. A major local absorbance maximum for FAD is observed at 450 nm, with an extinction coefficient of 11,300 M−1 cm−1.
== tRNA biogenesis == In eukaryotic cells, tRNAs are transcribed by RNA polymerase III as pre-tRNAs in the nucleus. RNA polymerase III recognizes two highly conserved downstream promoter sequences: the 5′ intragenic control region (5′-ICR, D-control region, or A box), and the 3′-ICR (T-control region or B box) inside tRNA genes. The first promoter begins at +8 of mature tRNAs and the second promoter is located 30–60 nucleotides downstream of the first promoter. The transcription terminates after a stretch of four or more thymidines.
TMA-2 (2,4,5-trimethoxyamphetamine) is very similar in chemical structure to the monoaminergic neurotoxin 6-hydroxydopamine (2,4,5-trihydroxyphenethylamine). A variety of derivatives of TMA-2 (MMM) have been developed and studied, such as MEM among others.
== External links == FABP4+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human FABP4 genome location and FABP4 gene details page in the UCSC Genome Browser. PDBe-KB provides an overview of all the structure information available in the PDB for Human Fatty acid-binding protein, adipocyte PDBe-KB provides an overview of all the structure information available in the PDB for Mouse Fatty acid-binding protein, adipocyte
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.